共 111 条
[1]
Rugo HS(2016)Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline J Clin Oncol 34 3069-3103
[2]
Rumble RB(2018)4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4) Ann Oncol 29 1634-1657
[3]
Macrae E(2015)The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 16 25-35
[4]
Barton DL(2020)Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18) Breast Cancer Res Treat 183 419-428
[5]
Connolly HK(2016)Palbociclib and letrozole in advanced breast cancer N Engl J Med 375 1925-1936
[6]
Dickler MN(2019)Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up Breast Cancer Res Treat 174 719-729
[7]
Cardoso F(2015)Palbociclib in hormone-receptor–positive advanced breast cancer N Engl J Med 373 209-219
[8]
Senkus E(2018)Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3 Eur J Cancer 104 21-31
[9]
Costa A(2017)Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results Oncologist. 22 1028-1038
[10]
Papadopoulos E(2019)Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients Int J Clin Oncol 24 262-273